Platelet Pharmacology and Therapy
Volume 5
Series: Platelets in Thrombotic and Non-Thrombotic Disorders;
- Publisher's listprice EUR 160.49
-
67 742 Ft (64 516 Ft + 5% VAT)
The price is estimated because at the time of ordering we do not know what conversion rates will apply to HUF / product currency when the book arrives. In case HUF is weaker, the price increases slightly, in case HUF is stronger, the price goes lower slightly.
- Discount 12% (cc. 8 129 Ft off)
- Discounted price 59 613 Ft (56 774 Ft + 5% VAT)
Subcribe now and take benefit of a favourable price.
Subscribe
67 742 Ft
Availability
Not yet published.
Why don't you give exact delivery time?
Delivery time is estimated on our previous experiences. We give estimations only, because we order from outside Hungary, and the delivery time mainly depends on how quickly the publisher supplies the book. Faster or slower deliveries both happen, but we do our best to supply as quickly as possible.
Product details:
- Publisher Springer Nature Switzerland
- Date of Publication 8 October 2025
- Number of Volumes 1 pieces, Book
- ISBN 9783031963599
- Binding Hardback
- No. of pages336 pages
- Size 279x210 mm
- Language English
- Illustrations V, 336 p. 42 illus., 36 illus. in color. Illustrations, black & white 700
Categories
Long description:
This five-volume series provides clinicians with a detailed, up-to-date, well-referenced overview of the latest developments in this rapidly expanding feld. It serves as an
authoritative guide to the diagnosis and treatment of platelet disorders.The primary audience for the series is clinicians, residents and fellows in internal medicine,
cardiology and haematology, as well as clinicians (e.g. neurologists, nephrologists, rheumatologists) and basic scientists who may be concerned with disorders and
cellular mechanisms involving platelets.
Table of Contents:
Chapter 106: Aspirin.- Chapter 107: P2Y12 inhibitors.- Chapter 108: GPIIb/IIIa antagonists.- Chapter 109: PAR antagonists.- Chapter 110: PDE-adenosine reuptake-inhibitor agents.- Chapter 111: Nitric oxide-releasing or enhancing agents.- Chapter 112: Platelet puringeric receptors as targets for novel anti-inflammatory drugs.- Chapter 113: Novel approaches to antiplatelet therapy.- Chapter 114: Antiplatelet therapy in coronary artery disease.- Chapter 115: Antiplatelet therapy for TIA/stroke.- Chapter 116: Antiplatelet therapy for PAD.- Chapter 117: Laboratory monitoring-guided antiplatelet therapy.- Chapter 118: Antiplatelet therapy for venous thromboembolism.- Chapter 119: Platelets in regenerative medicine.- Chapter 120: Platelet transfusions.- Chapter 121: TPO agonists and agents under development to increase platelet count.- Chapter 122: In vitro generated engineered or enhanced platelets.- Chapter 123: Platelets for gene therapy.- Chapter 124: Platelets as carriers for antitumor therapy.
More
